PURPOSE: We utilized the large, prospective NIH-AARP Diet and Health Study to further explore the hypothesis, suggested by two recent prospective cohort studies, that increased intake of coffee, tea, soda, and/or caffeine is associated with reduced adult glioma risk. METHODS: At baseline in 1995-1996, dietary intake, including coffee, tea, and soda, was assessed with a food frequency questionnaire. We used Cox proportional hazards models to calculate adjusted hazard ratios (HR) and 95 % confidence intervals (CI) for glioma risk in relation to beverage intake. RESULTS: During follow-up of 545,771 participants through 2006, 904 participants were diagnosed with glioma. We found no trends of decreasing glioma risk with increasing intake of specific beverages or total caffeine. HR patterns for consumption of the caffeinated versus decaffeinated form of each beverage were inconsistent with a specific caffeine effect. HR patterns of reduced glioma risk for most categories of beverage intake greater than "none" prompted a post hoc analysis that revealed borderline-significant inverse associations for any versus no intake of tea (HR = 0.84; 95 % CI, 0.69-1.03), total coffee plus tea (HR = 0.70; 95 % CI, 0.48-1.03), and soda (HR = 0.82; 95 % CI, 0.67-1.01). CONCLUSIONS: The borderline-significant inverse associations could be explained by a threshold effect in which any beverage intake above a low level confers a beneficial effect, most likely due to beverage constituents other than caffeine. They could also be explained by non-drinkers of these beverages sharing unknown extraneous characteristics associated with increased glioma risk, or by chance.
PURPOSE: We utilized the large, prospective NIH-AARP Diet and Health Study to further explore the hypothesis, suggested by two recent prospective cohort studies, that increased intake of coffee, tea, soda, and/or caffeine is associated with reduced adult glioma risk. METHODS: At baseline in 1995-1996, dietary intake, including coffee, tea, and soda, was assessed with a food frequency questionnaire. We used Cox proportional hazards models to calculate adjusted hazard ratios (HR) and 95 % confidence intervals (CI) for glioma risk in relation to beverage intake. RESULTS: During follow-up of 545,771 participants through 2006, 904 participants were diagnosed with glioma. We found no trends of decreasing glioma risk with increasing intake of specific beverages or total caffeine. HR patterns for consumption of the caffeinated versus decaffeinated form of each beverage were inconsistent with a specific caffeine effect. HR patterns of reduced glioma risk for most categories of beverage intake greater than "none" prompted a post hoc analysis that revealed borderline-significant inverse associations for any versus no intake of tea (HR = 0.84; 95 % CI, 0.69-1.03), total coffee plus tea (HR = 0.70; 95 % CI, 0.48-1.03), and soda (HR = 0.82; 95 % CI, 0.67-1.01). CONCLUSIONS: The borderline-significant inverse associations could be explained by a threshold effect in which any beverage intake above a low level confers a beneficial effect, most likely due to beverage constituents other than caffeine. They could also be explained by non-drinkers of these beverages sharing unknown extraneous characteristics associated with increased glioma risk, or by chance.
Authors: Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Yikyung Park; Panagiota N Mitrou; Victor Kipnis; Albert Hollenbeck; Arthur Schatzkin; Michael F Leitzmann Journal: Am J Epidemiol Date: 2007-10-12 Impact factor: 4.897
Authors: Steven C Moore; Preetha Rajaraman; Robert Dubrow; Amy S Darefsky; Corinna Koebnick; Albert Hollenbeck; Arthur Schatzkin; Michael F Leitzmann Journal: Cancer Res Date: 2009-10-06 Impact factor: 12.701
Authors: David J Cote; Alaina M Bever; Kathryn M Wilson; Timothy R Smith; Stephanie A Smith-Warner; Meir J Stampfer Journal: Int J Cancer Date: 2019-07-26 Impact factor: 7.396
Authors: Quinn T Ostrom; Maral Adel Fahmideh; David J Cote; Ivo S Muskens; Jeremy M Schraw; Michael E Scheurer; Melissa L Bondy Journal: Neuro Oncol Date: 2019-11-04 Impact factor: 12.300
Authors: Erikka Loftfield; Neal D Freedman; Barry I Graubard; Albert R Hollenbeck; Fatma M Shebl; Susan T Mayne; Rashmi Sinha Journal: J Natl Cancer Inst Date: 2015-01-20 Impact factor: 13.506
Authors: M Z Braganza; P Rajaraman; Y Park; P D Inskip; N D Freedman; A R Hollenbeck; A Berrington de González; C M Kitahara Journal: Br J Cancer Date: 2013-12-12 Impact factor: 7.640
Authors: Ai Seon Kuan; Jane Green; Cari M Kitahara; Amy Berrington De González; Tim Key; Gillian K Reeves; Sarah Floud; Angela Balkwill; Kathryn Bradbury; Linda M Liao; Neal D Freedman; Valerie Beral; Siân Sweetland Journal: Neuro Oncol Date: 2019-07-11 Impact factor: 12.300